HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.8%

Neg 0% Neu 87.8% Pos 0%

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.